Open Access

Potential five‑mRNA signature model for the prediction of prognosis in patients with papillary thyroid carcinoma

  • Authors:
    • Lin‑Kun Zhong
    • Xiao‑Xiong Gan
    • Xing‑Yan Deng
    • Fei Shen
    • Jian‑Hua Feng
    • Wen‑Song Cai
    • Qiong‑Yao Liu
    • Jian‑Hang Miao
    • Bing‑Xing Zheng
    • Bo Xu
  • View Affiliations

  • Published online on: June 26, 2020     https://doi.org/10.3892/ol.2020.11781
  • Pages: 2302-2310
  • Copyright: © Zhong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Although the mortality rate of papillary thyroid carcinoma (PTC) is relatively low, the recurrence rates of PTC remain high. The high recurrence rates are related to the difficulties in treatment. Gene expression profiles has provided novel insights into potential therapeutic targets and molecular biomarkers of PTC. The aim of the present study was to identify mRNA signatures which may categorize PTCs into high‑and low‑risk subgroups and aid with the predictions for prognoses. The mRNA expression profiles of PTC and normal thyroid tissue samples were obtained from The Cancer Genome Atlas (TCGA) database. Differentially expressed mRNAs were identified using the ‘EdgeR’ software package. Gene signatures associated with the overall survival of PTC were selected, and enrichment analysis was performed to explore the biological pathways and functions of the prognostic mRNAs using the Database for Visualization, Annotation and Integration Discovery. A signature model was established to investigate a specific and robust risk stratification for PTC. A total of 1,085 differentially expressed mRNAs were identified between the PTC and normal thyroid tissue samples. Among them, 361 mRNAs were associated with overall survival (P<0.05). A 5‑mRNA prognostic signature for PTC (ADRA1B, RIPPLY3, PCOLCE, TEKT1 and SALL3) was identified to classify the patients into high‑and low‑risk subgroups. These prognostic mRNAs were enriched in Gene Ontology terms such as ‘calcium ion binding’, ‘enzyme inhibitor activity’, ‘carbohydrate binding’, ‘transcriptional activator activity’, ‘RNA polymerase II core promoter proximal region sequence‑specific binding’ and ‘glutathione transferase activity’, and Kyoto Encyclopedia of Genes and Genomes signaling pathways such as ‘pertussis’, ‘ascorbate and aldarate metabolism’, ‘systemic lupus erythematosus’, ‘drug metabolism‑cytochrome P450 and ‘complement and coagulation cascades’. The 5‑mRNA signature model may be useful during consultations with patients with PTC to improve the prediction of their prognosis. In addition, the prognostic signature identified in the present study may reveal novel therapeutic targets for patients with PTC.

Related Articles

Journal Cover

September-2020
Volume 20 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhong LK, Gan XX, Deng XY, Shen F, Feng JH, Cai WS, Liu QY, Miao JH, Zheng BX, Xu B, Xu B, et al: Potential five‑mRNA signature model for the prediction of prognosis in patients with papillary thyroid carcinoma. Oncol Lett 20: 2302-2310, 2020
APA
Zhong, L., Gan, X., Deng, X., Shen, F., Feng, J., Cai, W. ... Xu, B. (2020). Potential five‑mRNA signature model for the prediction of prognosis in patients with papillary thyroid carcinoma. Oncology Letters, 20, 2302-2310. https://doi.org/10.3892/ol.2020.11781
MLA
Zhong, L., Gan, X., Deng, X., Shen, F., Feng, J., Cai, W., Liu, Q., Miao, J., Zheng, B., Xu, B."Potential five‑mRNA signature model for the prediction of prognosis in patients with papillary thyroid carcinoma". Oncology Letters 20.3 (2020): 2302-2310.
Chicago
Zhong, L., Gan, X., Deng, X., Shen, F., Feng, J., Cai, W., Liu, Q., Miao, J., Zheng, B., Xu, B."Potential five‑mRNA signature model for the prediction of prognosis in patients with papillary thyroid carcinoma". Oncology Letters 20, no. 3 (2020): 2302-2310. https://doi.org/10.3892/ol.2020.11781